Chen Chun-Fan, Chen Fu-An, Tan Ann Charis, Lee Tsung-Lun, Chan Chia-Hao, Lin Chih-Ching
School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Division of Nephrology, Department of Internal Medicine, National Yang-Ming University Hospital, Yilan, Taiwan.
Heart Vessels. 2019 Mar;34(3):435-441. doi: 10.1007/s00380-018-1259-5. Epub 2018 Sep 18.
Ankle brachial index (ABI) is a diagnostic tool for peripheral artery disease (PAD), which is an important issue in hemodialysis (HD) patients. We enrolled 198 maintenance HD patients in this study. PAD is defined as ABI ≤ 0.90. Only PAD patients received far-infrared (FIR) therapy using the WS TY101 FIR emitter for 40 min during each HD session, three times weekly for 6 months. The ABI was measured at the bilateral lower extremities for 4 times [pre-dialytic timing (0 min) and 40 min after the initiation of HD session at both day 0 and 6 months after the FIR therapy]. The primary outcome is the change in ABI. There were 51 out of 198 patients with PAD. In comparison with the period without FIR therapy in the 51 PAD patients, 6 months of FIR therapy significantly improved the ABI of the right/left side for 0 min (from 0.77 ± 0.19 to 0.81 ± 0.20, p = 0.027/0.79 ± 0.20 to 0.81 ± 0.17, p = 0.049), 40 min during HD (from 0.73 ± 0.23 to 0.83 ± 0.19, p < 0.001/from 0.77 ± 0.21 to 0.83 ± 0.18, p < 0.001), and the incremental change between 0 and 40 min (from - 0.04 ± 0.14 to 0.05 ± 0.13, p = 0.007/from - 0.05 ± 0.13 to 0.03 ± 0.11, p = 0.012), respectively. In conclusion, the application of FIR therapy for 40 min, three times weekly for 6 months, has improved the ABI of both lower extremities, thus providing a new strategy of PAD treatment in HD patients.
踝臂指数(ABI)是一种用于诊断外周动脉疾病(PAD)的工具,外周动脉疾病在血液透析(HD)患者中是一个重要问题。我们在本研究中纳入了198例维持性血液透析患者。PAD定义为ABI≤0.90。仅PAD患者在每次血液透析期间使用WS TY101远红外发射器接受40分钟的远红外(FIR)治疗,每周三次,共6个月。在双侧下肢测量ABI 4次[透析前(0分钟)以及FIR治疗后第0天和第6个月血液透析开始后40分钟]。主要结局是ABI的变化。198例患者中有51例患有PAD。与51例PAD患者未接受FIR治疗的时期相比,6个月的FIR治疗显著改善了右侧/左侧0分钟时的ABI(从0.77±0.19至0.81±0.20,p = 0.027/从0.79±0.20至0.81±0.17,p = 0.049)、血液透析期间40分钟时的ABI(从0.73±0.23至0.83±0.19,p <0.001/从0.77±0.21至0.83±0.18,p <0.001)以及0至40分钟之间的增量变化(从-0.04±0.14至0.05±0.13,p = 0.007/从-0.05±0.13至0.03±0.11,p = 0.012)。总之,每周三次、每次40分钟、共6个月的FIR治疗应用改善了双下肢的ABI,从而为血液透析患者的外周动脉疾病治疗提供了一种新策略。